Nasus Pharma

Nasus Pharma announced a leadership change on July 28, 2026. Nasus Pharma appointed Brendan P. O’Grady Chief Executive Officer, succeeding Dan Teleman, to lead its next phase of growth with an initial focus on the commercial potential of NS002.

What changed

Brendan P. O’Grady was named Chief Executive Officer. O’Grady succeeds Dan Teleman, with the leadership transition effective July 27, 2026.

• Leader: Brendan P. O’Grady
• Role: Chief Executive Officer
• Effective: July 27, 2026
• Announcement date: July 28, 2026

Leadership background

O’Grady has more than three decades of global leadership experience across corporate strategy, business development, commercialization, market access, partnerships, and global product launches, the company said. He spent 21 years at Teva Pharmaceuticals in commercial roles, rising to CEO of Teva USA and EVP North America Commercial, and has also served as CEO of Assertio Holdings. He was a director of American Well Corporation from 2015 to 2021.

The mandate

Nasus Pharma said O’Grady will lead the company’s next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the pipeline and business development, and maximizing the value of the Nasax intranasal platform. Chairman Udi Gilboa said that as NS002 advances toward a pivotal trial in the fourth quarter of 2026, the company’s strategic focus is increasingly centered on pre-commercial planning.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: Nasus Pharma leadership announcement.